Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

NCT02089256 on ClinicalTrials.gov · last registry update 2015-04-01

A small phase 4 — 10 participants, against a typical 75. The sponsor logged completion for March 2015. Primary outcome, as filed: Change in the glucose-sensitivity of the beta cells.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Tartu
Sponsor type: Other
Enrollment: 10
Started: 2014-06
Primary completion: 2015-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in the glucose-sensitivity of the beta cells

Conditions studied

Healthy

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.